AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02950571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Picture Frame
Description: The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
Study NCT02950571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: High level of support from an interdisciplinary team.
Study NCT05026918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCPT
Description: Postural Drainagewith percussion and vibration
Study NCT05026918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACBT
Description: ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
Study NCT01680796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily
Study NCT01156077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral TR-701 FA 200 mg will be given as a single oral dose
Study NCT01156077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
Study NCT00064025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01680796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8
Study NCT01680796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
Study NCT04146883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
Study NCT03963388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
Study NCT04405570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 200 mg
Description: Oral capsule of molnupiravir
Study NCT04405570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg
Description: Oral capsule of molnupiravir
Study NCT00064025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Description: Given IM
Study NCT00064025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical hysterectomy
Study NCT03478826 — intervention group
Intervention type: OTHER
Intervention: ILD
Description: 100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
Study NCT03478826 — intervention group
Intervention type: OTHER
Intervention: Healthy
Description: 100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
Study NCT03478826 — intervention group
Intervention type: OTHER
Intervention: Pneumonia
Description: 100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Study NCT03987750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate 150mg
Description: 150 mg (free base)
Study NCT03987750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate 100mg
Description: 100 mg (free base)
Study NCT03987750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide Methanesulfonate matching placebo
Description: placebo
Study NCT02095301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Beverage
Study NCT00707356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
Study NCT03035760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
Study NCT01397851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insecticide-treated net (BASF Incerceptor)
Description: One per farmer, once during the 2010-2011 season
Study NCT01442298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb occlusion pressure (LOP)
Description: The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
Study NCT04405570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg
Description: Oral capsule of molnupiravir
Study NCT04405570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBO)
Description: placebo oral capsule
Study NCT04295122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser
Description: A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded.
Study NCT01175018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg s.c. daily for 14 days
Study NCT01175018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
Study NCT00084630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT01442298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional measurement method
Description: Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
Study NCT02339467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GO-OUT program
Description: Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
Study NCT02339467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented outdoor walking workshop
Description: The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
Study NCT02968355 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study NCT00084630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00887952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious dentine
Description: All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
Study NCT00887952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise excavation
Description: The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
Study NCT02581709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Countering cognitive impairment
Description: The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
Study NCT02094599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 10 mg
Description: Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
Study NCT02094599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 30 mg
Description: Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
Study NCT03625661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferinject 50mg/ml, one injection
Study NCT02094599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo provided in capsules or as an oral solution in syringes.
Study NCT04964011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Board game intervention
Description: In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
Study NCT04964011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Board game intervention
Description: In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
Study NCT02102750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative free tafluprost opthalmic solution
Description: 0.0015% eye drops q.d, in both eyes for 7 to 9 days
Study NCT04341051 — intervention group
Intervention type: OTHER
Intervention: Case
Description: Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
Study NCT02894593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol free essential oils mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT02894593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: alcohol essential oils mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT02894593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.20% chlorhexidine mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT02894593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT01151436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid dermal fillers
Description: 1 injection per indication and 1 touch-up injection if necessary
Study NCT01952860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
Study NCT01952860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
Study NCT00528151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin
Description: curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
Study NCT05975229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knitting and education (pamphlet)
Description: Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
Study NCT05975229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education (pamphlet)
Description: Receive only the pamphlet, not the knitting program.
Study NCT00679887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic compression
Description: Active Comparator, ischemic compression, 3 times a week,5 weeks
Study NCT03433625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural experiments for intolerance of uncertainty (BE-IU)
Description: CBT
Study NCT03972033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm.
Study NCT03972033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm.
Study NCT04652648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
Study NCT01577121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: 50 mg / 6 hours during 5 days
Study NCT01577121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50 mg / 6 hours during 5 days
Study NCT02033226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane
Description: AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
Study NCT02033226 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Hydroxyapatite only)
Description: The placebo group was treated with Hydroxyapatite graft placement only.
Study NCT06197282 — intervention group
Intervention type: PROCEDURE
Intervention: Major surgery involving general anesthesia
Description: EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
Study NCT03824509 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017.
Study NCT02882477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Study NCT02943083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Exercise
Description: Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
Study NCT02943083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Exercise
Description: Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
Study NCT00591578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
Study NCT00591578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.